Nikhil Mutyal
Head of Search and Evaluation- Respiratory and Immunology AstraZeneca
Nikhil Mutyal, Ph.D., is Global Head of Search and Evaluation – Respiratory & Immunology at AstraZeneca, where he leads a team focused on R&I BD across all stages, geographies and modalities. A pharmaceutical business development and strategic planning leader, he is passionate about building teams that create value through external innovation and transformative deals, with a knack for identifying “diamonds in the rough.” His work sits at the intersection of science, strategy, and deals, shaping partnerships and driving pipeline impact. He has held BD&L and corporate development roles at Merck, Jazz Pharmaceuticals, and AVEO Oncology.
Seminars
Take your seat across the table from pharma and VC leaders actively evaluating emerging platforms in this interactive roundtable setting. Understand their therapeutic interests and investment considerations, then showcase your pipeline and align on partnership expectations through rare face-to-face interactions to ignite interest in your pipeline and cultivate collaborative, strategic partnerships.
- Understand pharma and VC therapies of interest, considering in vivo and beyond to identify high-value opportunities
- For pharma and investors, engage with senior leaders from pioneering biotech and academics early to uncover opportunities for collaboration. • For biotech, gain actionable insights by hearing what your peers are developing and understanding first-hand the direction of pharma and biotech innovation
- Leave with new connections, strategic alignment opportunities, and practical knowledge to advance your projects
- Identifying the ideal development stage for engagement to ensure timely and effective collaboration
- Detailing therapies of interest, considering in vivo and beyond to identify high-value opportunities
- Discussing collaboration processes beyond initial interest to secure
- Connect directly with leading experts in an interactive roundtable setting, sharing your work and showcasing your assets in focused, face-to-face conversations
- For pharma and investors, engage with senior leaders from pioneering biotech and academics early to uncover opportunities for collaboration
- For biotech, gain actionable insights by hearing what your peers are developing and understand first-hand the direction of pharma and biotech innovation
- Leave with new connections, strategic alignment opportunities, and practical knowledge to advance your projects
